We collected 244 human GC samples from The Cancer Genome Atlas (TCGA) database and analysed the overall survival of CD56 in GC patients; the results revealed that higher CD56 expression did not mean longer or better overall survival (Figure S2D). This evidence concerns the gene NCAM1 and gastric cancer.